If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Gavin Robertson's research program focuses on malignant melanoma, the most deadly form of skin cancer. The central goal of his program is to unravel the biology and signaling pathways involved in melanoma tumor development in order to develop the next generation of therapeutic agents to treat this disease. Specifically, it involves identification and validation of novel therapeutic targets, discovery and development of new therapies and clinical evaluation of these drugs in patients.

Generally,the types of studies occurring the Robertson laboratory are:

Genetic and cell culture studies using animal and human models are used to identify and validate the involvement of candidate melanoma-causing genes. A recent example is the discovery of Akt3 involvement in approximately 70 percent of human melanomas.

Drug screens and medicinal chemistry are used to identify and develop new therapeutic agents. A recent example is the melanoma-treating drug ISC-4, which targets Akt3 signaling.

Nanotechnology and bioengineering are used to better deliver experimental agents into cancer cells. A recent example of this is the use of nanoliposomes and ultrasound that deliver therapeutic siRNA into melanoma cells.

Finally, agents are tested in the clinic for toxicity and tumor inhibitory efficacy. A recent example is a killed mycobacterium called CADI-5 that is being evaluated in clinical trials.

The ultimate goal of Dr. Robertson's translational research program is to develop better therapeutics for the treatment of melanoma based on the biology of the disease.

Fingerprint Dive into the research topics where Gavin Robertson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents

    Dinavahi, S. S., Gowda, R., Bazewicz, C. G., Battu, M. B., Lin, J. M., Chitren, R. J., Pandey, M. K., Amin, S., Robertson, G. P. & Gowda, K., Feb 1 2020, In : European Journal of Medicinal Chemistry. 187, 111962.

    Research output: Contribution to journalArticle

  • Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent

    Dinavahi, S. S., Gowda, R., Gowda, K., Bazewicz, C. G., Chirasani, V. R., Battu, M. B., Berg, A., Dokholyan, N. V., Amin, S. & Robertson, G. P., Feb 1 2020, In : Molecular cancer therapeutics. 19, 2, p. 447-459 13 p.

    Research output: Contribution to journalArticle

  • The role of exosomes in metastasis and progression of melanoma

    Gowda, R., Robertson, B. M., Iyer, S., Barry, J., Dinavahi, S. S. & Robertson, G. P., Apr 2020, In : Cancer Treatment Reviews. 85, 101975.

    Research output: Contribution to journalReview article

  • Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

    Dinavahi, S. S., Bazewicz, C. G., Gowda, R. & Robertson, G. P., Oct 2019, In : Trends in Pharmacological Sciences. 40, 10, p. 774-789 16 p.

    Research output: Contribution to journalReview article

  • 8 Scopus citations

    Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

    Bazewicz, C. G., Dinavahi, S. S., Schell, T. D. & Robertson, G. P., Jan 2019, In : Immunology. 156, 1, p. 47-55 9 p.

    Research output: Contribution to journalReview article

  • 9 Scopus citations